Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CITIGROUP INC.

(C)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Citi : Appointed as Depositary Bank for Molecular Partners AG's ADR Programme

06/21/2021 | 01:01am EDT

Citi, acting through Citibank N.A., has been appointed by Molecular Partners AG (“Molecular Partners”), a clinical-stage biotech company, to act as depositary bank for its American Depositary Receipt (“ADR”) programme.

Molecular Partners’ American Depositary Shares (“ADS”) trade on the Nasdaq Global Market under the symbol “MOLN”. Each ADS represents one ordinary share of the company.

Andreas Emmenegger, Molecular Partners’ CFO, said: “We are pleased to be working with Citi as part of the team supporting our new Nasdaq listing.”

Commenting on the appointment, Dirk Jones, Global Head of Issuer Services, at Citi said: “We look forward to supporting Molecular Partners’ ADR programme and expanding the company’s investor outreach through the expertise of our Investor Relations Advisory team and the breadth of our global equity distribution network.”

For more information on Citi’s Depositary Receipt Services, please visit www.citi.com/dr

About Molecular Partners

Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

About Citi

Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions. Citi provides consumers, corporations, governments and institutions with a broad range of financial products and services, including consumer banking and credit, corporate and investment banking, securities brokerage, transaction services, and wealth management.

Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi


ę Business Wire 2021
All news about CITIGROUP INC.
08/03DEUTSCHE BANK : Investment bank Lazard raises pay for junior U.S. analysts
RE
08/03CREDIT SUISSE : hires Citigroup banker Alibhai to lead media investment banking
RE
08/03MOVES-Credit Suisse hires Citigroup banker Alibhai to lead media M&A
RE
08/03FTSE 100 Closes Higher After Positive Corporate Earnings
DJ
08/03AUTOHOME : Citigroup Downgrades Autohome to Neutral from Buy, Adjusts Price Targ..
MT
08/03RAYMOND JAMES FINANCIAL : Citigroup Adjusts Price Target on Raymond James Financ..
MT
08/03SOLAREDGE TECHNOLOGIES : Citigroup Upgrades SolarEdge Technologies to Buy From N..
MT
08/03BAOZUN : Citigroup Adjusts Baozun's Price Target to $36 From $57, Reiterates Buy..
MT
08/03ARISTA : Citigroup Adjusts Arista Networks' Price Target to $400 From $325, Main..
MT
08/03REYNOLDS CONSUMER PRODUCTS : Citigroup Adjusts Price Target on Reynolds Consumer..
MT
More news
Financials (USD)
Sales 2021 70 815 M - -
Net income 2021 20 471 M - -
Net Debt 2021 - - -
P/E ratio 2021 6,93x
Yield 2021 2,99%
Capitalization 142 B 142 B -
Capi. / Sales 2021 2,01x
Capi. / Sales 2022 1,98x
Nbr of Employees 214 000
Free-Float 65,6%
Chart CITIGROUP INC.
Duration : Period :
Citigroup Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CITIGROUP INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 68,88 $
Average target price 83,80 $
Spread / Average Target 21,7%
EPS Revisions
Managers and Directors
Jane Nind Fraser President, Chief Executive Officer & Director
Mark A. L. Mason Chief Financial Officer
John C. Dugan Chairman
Mike Whitaker Head-Operations & Technology
Mary Mcniff Chief Compliance Officer
Sector and Competitors